RT Journal Article
SR Electronic
T1 Study of Epidemiological Characteristics and In-silico Analysis of the Effect of Interventions in the SARS-CoV-2 Epidemic in India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.05.20053884
DO 10.1101/2020.04.05.20053884
A1 Archisman Mazumder
A1 Vishwesh Bharadiya
A1 Parul Berry
A1 Mehak Arora
A1 Mudit Agarwal
A1 Mohak Gupta
A1 Giridara Gopal Parameswaran
A1 Priyamadhaba Behera
YR 2020
UL http://medrxiv.org/content/early/2020/04/14/2020.04.05.20053884.abstract
AB After SARS-CoV-2 set foot in India, the Government took a number of steps to limit the spread of the disease in the country. This study involves assessing how the disease affected the population in the initial days of the epidemic. Data was collected from government-controlled and crowdsourced websites and analyzed. Studying age and sex parameters of 413 Indian COVID-19 patients, the median age of the affected individuals was found to be 36 years (IQR, 25-54) with 20-39 years males being the most affected group. The number of affected males (66.34%) was more than that of the females (33.66%). Using Susceptible-Infected-Removed (SIR) model, the range of contact rate (β) of India was calculated and the role of public health interventions was assessed. If current contact rate continues, India may have 5583 to 13785 active cases at the end of 21 days lockdown.Article Summary Line The study gives the epidemiological characteristics of the SARS-CoV-2 epidemic in India, where unlike other countries, the 20-39 years males are most affected, and the SIR model predicts the probable number of cases of COVID-19 by the end of the 21 days lockdown in the country, which will help to develop appropriate public health interventions to control the COVID-19 epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding recievedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData taken from publicly available crowdsourced and government databases https://www.covid19india.org/ IQRInterquartile RangeSIRSusceptible-Infected-Removed